Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results

Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings

U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings. European and Asian markets closed mostly lower.

Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results

US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change Agents down 29%, and Xiao-I down 21%.

Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma.

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.

Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug

Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms issued price target increases following the commercial rollout of the company's first-in-class oncology therapy.

Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.